Phase 1Completed

Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma

Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Sponsor
Cogent Biosciences, Inc. (Industry)
Enrollment
34 enrolled
Conditions
Lymphoma
Interventions
ACTR087; rituximab
Ages
adults, older adults
Registry
NCT02776813

Full record on ClinicalTrials.gov

From the registry

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.

Primary outcomes

  • Safety as assessed by dose limiting toxicities (DLTs)
  • Safety as assessed by determination of the maximum tolerated dose (MTD)
  • Safety as assessed by determination of the recommended phase 2 dose (RP2D)
  • Safety as assessed by and adverse events, laboratory assessments and physical examinations

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered